Acetosal Resistance In Coronary Artery Disease Between And Within Type 2 Diabetes Mellitus Patients.

Abstract

Acetosal reduces the odds of an arterial thrombotic event in high risk patients. However, 10%-20% of patients with an arterialthrombotic event who are treated with acetosal have a recurrent arterial thrombotic event during long-term follow up. Acetosalresistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, andpercutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and Type 2 Diabetes Mellitus. Patients were dividedinto two groups of ten patients each, 10 patients Coronary Artery Diseases with Type 2 Diabetes Mellitus and 10 patients non-Type 2Diabetes Mellitus. The sampling of this cross sectional study was conducted at departement of Cardiology Dr. Soetomo HospitalSurabaya during July-August 2014. Data from 20 patients were analyzed after exclusion due to protocol violations. All subjects wereon Asetosal 100 mg/day. Four (40%) patients with Type 2 Diabetes Mellitus were acetosal non-responders, acetosal resistance wasobserved in 3 (30%) of nondiabetic patients (p=1.000). In conclusion, no difference has been found on acetosal resistance incoronary artery disease patients with or without Type 2 Diabetes Mellitus. (FMI 2015;51:137-141